The PRIMO initiative aims to monitor and prevent antibiotic resistance and healthcare-associated infections in community care settings and the medical-social sector. The 2024 national data on antibiotic resistance in community care settings and nursing homes focus on three bacterial species of interest (Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus). From January 1 to December 31, 2024, susceptibility testing results for E. coli, K. pneumoniae, and S. aureus isolated from diagnostic specimens were collected from a network of 2,015 clinical laboratories (LBM) located across the 13 regions of mainland France and Réunion. Antibiogram data for strains isolated from specimens from patients living at home or residents of long-term care facilities were included in the analysis. Screening specimens and specimens from healthcare facilities were excluded. The proportions of antibiotic resistance were calculated at the national and regional levels, specifically for third-generation cephalosporins (3GC), carbapenems, and fluoroquinolones (FQ), including a description of trends, a comparison between 3G-susceptible and 3G-resistant strains, the proportions of strains susceptible and resistant to one or more antibiotics (multidrug-resistant bacteria), and incidence. Statistical analyses were performed using Student’s t-test or analysis of variance. In 2024, 962,944 antibiotic susceptibility tests were conducted on Enterobacteriaceae strains isolated from urine samples (of which 83.4% were E. coli and 11.5% were K. pneumoniae). Among patients living at home, 4.3% of E. coli isolates were resistant to C3G and 3.7% produced extended-spectrum beta-lactamase (ESBL). Among nursing home residents, resistance to C3G was observed in 8.9% of E. coli strains, and 7.8% were ESBL-producing. Resistance to FQs in E. coli was 10.8% for strains isolated from home-dwelling patients and 14.2% for those isolated from nursing home residents. In K. pneumoniae, ESBL production was observed in 7.9% of strains isolated from home-dwelling patients and 20.0% of those isolated from nursing home residents, while 10.4% of strains were resistant to fluoroquinolones among home-dwelling patients and 20.5% among nursing home residents. Among home-based patients, 375 strains of E. coli and 155 strains of K. pneumoniae produced a carbapenemase, and in nursing homes, 18 strains of E. coli and 12 strains of K. pneumoniae. For S. aureus, 42,363 susceptibility tests were included (excluding urine samples), with 6.1% of methicillin-resistant strains isolated from patients living at home and 35.4% in nursing homes. In 2024, the percentage of urinary E. coli strains producing ESBL was at its highest since 2017 (3.4%) in outpatient care and had also increased in nursing homes. In contrast, resistance to fluoroquinolones decreased in both outpatient care and nursing homes. Although the number of carbapenemase-producing Enterobacteriaceae isolated from diagnostic specimens remained low in 2024, their steady increase warrants monitoring. Both fosfomycin and nitrofurantoin maintained good efficacy against E. coli strains in both settings.